Incyte Corporation

Merus N.v.

Horacio G Nastri

Rebecca A Buonpane

Shaun M Stewart

Juan C Almagro

Jing Zhou

Wenqing Yao

Liangxing Wu

Xiaozhao Wang

Wenyu Zhu

Taisheng Huang

Chao Qi

Peter Niels Carlsen

Yingnan Chen

Yong Li

Patrick Mayes

Hui Wang

Simon Edward Plyte

Sean D Mckenna

Olivier Leger

Qi An

Gang Hao

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.

Anti-CD73 antibodies and uses thereof

The present disclosure relates to novel PD-1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain. The PD-1 binding domains of the present disclosure further provide a comparable, or equal or higher, potency in blocking ligand binding to human PD-1 than a reference PD-1 antibody. The present disclosure further relates to binding moieties comprising such PD-1 binding domains. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a PD-1 binding domain or binding moiety of the present disclosure. The present disclosure further relates to nucleic acids encoding the heavy chain variable region of the PD-1 binding domains, and a vector and cell comprising such nucleic acid.

PD-1 binding domains

Growing community of inventors

West Chester, PA, United States of America

Horacio G Nastri